Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Sleep disturbance and the effects of extended-release zolpidem during cannabis withdrawal.

Vandrey R, Smith MT, McCann UD, Budney AJ, Curran EM.

Drug Alcohol Depend. 2011 Aug 1;117(1):38-44. doi: 10.1016/j.drugalcdep.2011.01.003. Epub 2011 Feb 5.

2.

A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia.

Scharf MB, Roth T, Vogel GW, Walsh JK.

J Clin Psychiatry. 1994 May;55(5):192-9.

PMID:
8071269
3.

Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.

Roth T, Soubrane C, Titeux L, Walsh JK; Zoladult Study Group.

Sleep Med. 2006 Aug;7(5):397-406. Epub 2006 Jul 3.

PMID:
16815744
4.

Subjective versus objective evaluation of hypnotic efficacy: experience with zolpidem.

Kryger MH, Steljes D, Pouliot Z, Neufeld H, Odynski T.

Sleep. 1991 Oct;14(5):399-407.

PMID:
1759092
5.

Pilot controlled double-blind study of the hypnotic effects of zolpidem in patients with chronic 'learned' insomnia: psychometric and polysomnographic evaluation.

Herrmann WM, Kubicki ST, Boden S, Eich FX, Attali P, Coquelin JP.

J Int Med Res. 1993 Nov-Dec;21(6):306-22.

PMID:
8143886
6.

Zolpidem, a valuable alternative to benzodiazepine hypnotics for chronic insomnia?

Declerck A, Smits M.

J Int Med Res. 1999;27(6):253-63. Erratum in: J Int Med Res 2000;28(1):46.

PMID:
10726234
7.

Placebo-controlled sleep laboratory studies on the acute effects of zolpidem on objective and subjective sleep and awakening quality in nonorganic insomnia related to neurotic and stress-related disorder.

Saletu-Zyhlarz G, Anderer P, Brandstätter N, Dantendorfer K, Gruber G, Mandl M, Ritter K, Zoghlami A, Saletu B.

Neuropsychobiology. 2000;41(3):139-48.

PMID:
10754428
8.

[Contribution of zolpidem in the management of sleep disorders].

Lavoisy J, Zivkovic B, Benavides J, Perrault GH, Robert P.

Encephale. 1992 Jul-Aug;18(4):379-92. French.

PMID:
1363657
9.

Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia.

Bettica P, Squassante L, Groeger JA, Gennery B, Winsky-Sommerer R, Dijk DJ.

Neuropsychopharmacology. 2012 Apr;37(5):1224-33. doi: 10.1038/npp.2011.310. Epub 2012 Jan 11.

10.

Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder.

Fava M, Asnis GM, Shrivastava R, Lydiard B, Bastani B, Sheehan D, Roth T.

J Clin Psychopharmacol. 2009 Jun;29(3):222-30. doi: 10.1097/JCP.0b013e3181a390ba.

PMID:
19440075
11.

Zolpidem: clinical experience in psychiatric settings.

Undén M.

Pol J Pharmacol. 1994 Sep-Oct;46(5):483-5. Review.

PMID:
7894539
12.

Retrograde effects of triazolam and zolpidem on sleep-dependent motor learning in humans.

Morgan PT, Kehne JH, Sprenger KJ, Malison RT.

J Sleep Res. 2010 Mar;19(1 Pt 2):157-64. doi: 10.1111/j.1365-2869.2009.00757.x. Epub 2009 Aug 13.

13.

Sleep laboratory study on single and repeated dose effects of paroxetine, alprazolam and their combination in healthy young volunteers.

Barbanoj MJ, Clos S, Romero S, Morte A, Giménez S, Lorenzo JL, Luque A, Dal-Ré R.

Neuropsychobiology. 2005;51(3):134-47. Epub 2005 Apr 18.

PMID:
15838185
14.

Zolpidem for persistent insomnia in SSRI-treated depressed patients.

Asnis GM, Chakraburtty A, DuBoff EA, Krystal A, Londborg PD, Rosenberg R, Roth-Schechter B, Scharf MB, Walsh JK.

J Clin Psychiatry. 1999 Oct;60(10):668-76.

PMID:
10549683
15.

Effects of zolpidem and flunitrazepam on nocturnal sleep of women subjectively complaining of insomnia.

Declerck AC, Ruwe F, O'Hanlon JF, Vermeeren A, Wauquier A.

Psychopharmacology (Berl). 1992;106(4):497-501. Erratum in: Psychopharmacology (Berl) 1992;109(1-2):254.

PMID:
1579623
16.

Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group.

Elie R, Rüther E, Farr I, Emilien G, Salinas E.

J Clin Psychiatry. 1999 Aug;60(8):536-44.

PMID:
10485636
17.

Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study.

Roehrs TA, Randall S, Harris E, Maan R, Roth T.

J Psychopharmacol. 2012 Aug;26(8):1088-95. doi: 10.1177/0269881111424455. Epub 2011 Oct 16.

18.

Effects of zolpidem on cyclic alternating pattern, an objective marker of sleep instability, in Japanese patients with psychophysiological insomnia: a randomized crossover comparative study with placebo.

Ozone M, Yagi T, Itoh H, Tamura Y, Inoue Y, Uchimura N, Sasaki M, Shimizu T, Terzano MG, Parrino L.

Pharmacopsychiatry. 2008 May;41(3):106-14. doi: 10.1055/s-2008-1058104.

PMID:
18484552
19.

Efficacy and safety of zolpidem extended release in elderly primary insomnia patients.

Walsh JK, Soubrane C, Roth T.

Am J Geriatr Psychiatry. 2008 Jan;16(1):44-57. doi: 10.1097/JGP.0b013e3181256b01.

PMID:
18165461
20.

Effect of zolpidem on sleep architecture and its next-morning residual effect in insomniac patients: a randomized crossover comparative study with brotizolam.

Uchimura N, Nakajima T, Hayash K, Nose I, Hashizume Y, Ohyama T, Habukawa M, Kotorii N, Kuwahara H, Maeda H.

Prog Neuropsychopharmacol Biol Psychiatry. 2006 Jan;30(1):22-9. Epub 2005 Jul 25.

PMID:
16048734
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk